Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.57 |
| ▸ | CES1 | P23141 | 8/20 | 0.57 |
| ▸ | CES2 | O00748 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927729 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL380746 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2934619 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9449697 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL4156201 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2935238 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2926268 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2935093 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL145805 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2937329 | 1.00 | FAAH (0.57) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054293-A1 | BIOMARKER FOR PROSTATE CANCER | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-03-13 | — | — | WO | claimed |
| US-20250076301-A1 | BIOMARKER FOR PROSTATE CANCER | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-03-06 | — | — | US | claimed |
| US-8486478-B2 | Structured lipid compositions | International Great Brands LLC (US) | 2013-07-16 | — | — | US | claimed |
| EP-2057904-B1 | Structured lipid compositions | KRAFT FOODS GLOBAL BRANDS LLC (US) | 2012-04-25 | — | — | EP | claimed |
| US-7807138-B2 | Biomarkers of metabolic responses to hepatic drugs | METABOLON, INC. (US) | 2010-10-05 | — | — | US | claimed |
| US-20090123635-A1 | Structured Lipid Compositions | INTERCONTINENTAL GREAT BRANDS LLC | 2009-05-14 | — | — | US | claimed |
| EP-2057904-A1 | Structured lipid compositions | Kraft Foods Global Brands LLC (US) | 2009-05-13 | — | — | EP | claimed |
| US-12533133-B2 | Stapling device with knife movable to a shielded configuration | CILAG GMBH INTERNATIONAL (CH) | 2026-01-27 | — | — | US | disclosed |
| US-12376843-B2 | Tissue augmentation tacks for use with soft tissue fixation repair systems and methods | MEDOS INTERNATIONAL SÀRL (CH) | 2025-08-05 | — | — | US | disclosed |
| US-12371401-B2 | Dithienyl disulfiram derivatives as selective ALDH1A1 inhibitors | BATTERJEE MEDICAL COLLEGE (SA) | 2025-07-29 | — | — | US | disclosed |
| CN-120131633-A | Combination of urolithin and immunotherapy treatment | 阿马曾提斯公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-3412218-B1 | TISSUE AUGMENTATION TACKS FOR USE WITH SOFT TISSUE FIXATION REPAIR SYSTEMS | MEDOS INT SARL (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20250145565-A1 | DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS | BATTERJEE MEDICAL COLLEGE (SA) | 2025-05-08 | — | — | US | disclosed |
| US-20130115649-A1 | Methods and Reagents for Metabolomics and Histology in a Biological Sample and a Kit for the Same | METABOLON, INC. | 2013-05-09 | — | — | US | disclosed |
| EP-2462811-A1 | Structured lipid compositions | Kraft Foods Global Brands LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| EP-0686046-B1 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-05-24 | — | — | EP | disclosed |
| US-5767299-A | Contrast agents | NYCOMED IMAGING AS (NO) | 1998-06-16 | — | — | US | disclosed |
| EP-0686046-A1 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1995-12-13 | — | — | EP | disclosed |
| WO-1994019025-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371401-B2 | Dithienyl disulfiram derivatives as selective ALDH1A1 inhibitors | ALDH3A1, ALDH1A1, ADH1A | FAAH 1145/4885CES1 55/4885CES2 201/4885 |
| US-12533133-B2 | Stapling device with knife movable to a shielded configuration | PARL, CLPP, CLPTM1L | FAAH 1039/4885CES1 4264/4885CES2 2344/4885 |
| US-20250145565-A1 | DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS | ALDH3A1, ALDH1A1, ADH1A | FAAH 1145/4885CES1 55/4885CES2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.